Targeting tumors using nanoparticle platforms: A phase i study of a systemically administered gene therapy system

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 922-923

  Larson, Christopher ^a   Mendez, Natalie ^b   Reid, Tony ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE; GREEN FLUORESCENT PROTEIN; LIPOSOME; MALEIMIDE; NANOPARTICLE; PROTEIN P53; TRANSFERRIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BYSTANDER EFFECT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHEMICAL BOND; CHEMOSENSITIZATION; CORRELATION ANALYSIS; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; FATIGUE; FEVER; GENE MUTATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HYPOTENSION; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; NONVIRAL GENE DELIVERY SYSTEM; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 84877030220     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.76     Document Type: Note

References (16)

1. Senzer, N, Nemunaitis, J, Nemunaitis, D, Bedell, C, Edelman, G, Barve M et al. (2013). Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 21: 1096-1103.
2. Xu, L, Huang, CC, Huang, W, Tang, WH, Rait, A, Yin, YZ et al. (2002). Systemic tumor-targeted gene delivery by anti-transferrin receptor scFvimmunoliposomes. Mol Cancer Ther 1: 337-346.
3. Daniels, TR, Delgado, T, Rodriguez, JA, Helguera, G and Penichet, ML (2006). The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158.
4. Zhang, Y, Satterlee, A and Huang, L (2012). In vivo gene delivery by nonviral vectors: overcoming hurdles Mol Ther 20: 1298-1304.
5. Audouy, SL, de Leij, LF, Hoekstra, D and Molema, G (2002). In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 19: 1599-1605.
6. de Kanter, R, Monshouwer, M, Meijer, DK and Groothuis, GM (2002). Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr Drug Metab 3: 39-59.
7. Xu, L, Frederik, P, Pirollo, KF, Tang, WH, Rait, A, Xiang, LM et al. (2002). Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 13: 469-481.
8. Munro, AJ, Lain, S and Lane, DP (2005). p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92: 434-444.
9. Hoff, PM (2005). Is there a role for routine p53 testing in colorectal cancer J Clin Oncol 23: 7395-7396.
10. Robles, AI and Harris, CC (2010). Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2: a001016. doi: 10.1101/cshperspect.a001016.
11. Olivier, M, Petitjean, A, de Caron Fromentel, C, Hainaut, P, Ayed, A and Hupp, T (2011). TP53 mutations in human cancers: selection versus mutagenesis. In: Ayed, A and Hupp, T (eds). p53. Landes Bioscience-Springer: Austin, TX, pp 1-18.
12. Xu, M, Kumar, D, Srinivas, S, Detolla, LJ, Yu, SF, Stass, SA et al. (1997). Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 8: 177-185.
13. Yu, W, Pirollo, KF, Yu, B, Rait, A, Xiang, L, Huang, W et al. (2004). Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32: e48.
14. Hamada, M, Fujiwara, T, Hizuta, A, Gochi, A, Naomoto, Y, Takakura, N et al. (1996). The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122: 360-365.
15. Xu, L, Pirollo, KF and Chang, EH (2001). Tumortargeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 74: 115-128.
16. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.